Acne and rosacea: What's new for treatment?

Dursun, Recep; Daye, Munise; Durmaz, Koray

doi:10.1111/dth.13020

Cited by 17 publications

(12 citation statements)

References 11 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cyclines are broad-spectrum bacteriostatic antibiotics and are commonly prescribed for those who have significant number of papules and pustules [31]. Tetracyclines have multiple mechanisms of action including antibacterial effect, inhibition of pro-inflammatory mediators and tissue destructive enzymes, and modulation of innate immunity, but it is not known which mechanism is the most relevant in attenuating the papules/pustules.…”

Section: Discussionmentioning

confidence: 99%

Characterization and Analysis of the Skin Microbiota in Rosacea: Impact of Systemic Antibiotics

Woo

Lee

Cho

et al. 2020

JCM

View full text Add to dashboard Cite

Systemic antibiotics are extensively used to control the papules and pustules of rosacea. Hence, it is crucial to understand their impact on the rosacea skin microbiota which is thought to be perturbed. The purpose of this study was to compare the makeup and diversity of the skin microbiota in rosacea before and after taking oral antibiotics. We also compared the skin microbiota at baseline according to age and rosacea severity. A longitudinal cohort study was performed on 12 rosacea patients with papules/pustules and no recent use of oral and topical antimicrobials/retinoids. Patients were prescribed oral doxycycline, 100 mg, twice daily for six weeks. Skin areas on the cheek and nose were sampled for 16S ribosomal RNA gene sequencing at baseline, and after six weeks of doxycycline treatment. Eleven females and one male aged 20–79 (median 51) with a median Investigator’s Global Assessment score of 3 (moderate) were enrolled. At baseline, Staphylococcus epidermidis was the most dominant species followed by Cutibacterium acnes (formerly Propionibacterium acnes). In the 60 Over-age group, the prevalence of Cutibacterium acnes was lower than that of the 60 & Under-age group. Rosacea severity increased with age and was associated with a decrease in the relative abundance of Cutibacterium acnes and an increase of Snodgrassella alvi. Across all subjects, antibiotic treatment reduced clinical rosacea grades and was associated with an increase in the relative abundance of Weissella confusa (P = 0.008, 95% CI 0.13% to 0.61%). Bacterial diversity (alpha diversity) was not significantly altered by antibiotics treatment. Principal coordinates analysis showed mild clustering of samples by patient (ANOSIM, Analysis of Similarity, R = 0.119, P = 0.16) and scant clustering with treatment (ANOSIM, R = 0.002; P = 0.5). In conclusion, we believe that rosacea has a unique age-dependent characteristic (i.e., severity). Although we were not able to pinpoint a causative microbiota, our study provides a glimpse into the skin microbiota in rosacea and its modulation by systemic antibiotics.

show abstract

Section: Discussionmentioning

confidence: 99%

Characterization and Analysis of the Skin Microbiota in Rosacea: Impact of Systemic Antibiotics

Woo

Lee

Cho

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…Rosacea is a chronic and inflammatory disease with a series of facial skin manifestations, including flushing, nontransient erythema, papules/pustules, telangiectasia, and phymatous changes [1][2][3][4]. Secondary manifestations, such as itching, burning, or stinging, are often observed in patients with rosacea [5].…”

Section: Introductionmentioning

confidence: 99%

Rosacea Treatment: Review and Update

Zhang

Tang

Wang

et al. 2020

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Rosacea is a chronic and inflammatory skin disease characterized by flushing, nontransient erythema, papules/pustules, telangiectasia, and phymatous changes. Secondary manifestations, such as itching, burning, or stinging, are often observed in patients with rosacea. In 2017, a phenotype-based approach for diagnosis and classification was recommended. With the update of the diagnosis and classification of rosacea, treatment options for patients with rosacea have attracted the attention of dermatologists. Here, we summarize the latest advances in rosacea treatment, including skin care and cosmetic treatments, topical therapies, oral therapies, laser- and light-based therapies, injection therapies, treatments for specific types of rosacea, treatments for systemic comorbidities, and combination therapies. The impact of the phenotype-based approach on rosacea treatment and future directions are also discussed.

show abstract

“…6 A variety of treatment modalities have been reviewed, including skin care and cosmetic treatments, topical therapies, oral therapies, laser-and light-based therapies, injection therapies, and combination therapies, based on their anti-demodex, anti-inflammatory, and anti-angiogenesis effects. [36][37][38][39] However, recalcitrant, refractory, and persistent rosacea remains challenging in rosacea treatment. 12,40 Botulinum toxin, especially type A, has many off-label uses in aesthetic treatments.…”

Section: Discussionmentioning

confidence: 99%

Use of Botulinum Toxin in Treating Rosacea: A Systematic Review

Zhang

Tang

Wang

et al. 2021

CCID

View full text Add to dashboard Cite

Background Rosacea is a chronic skin disorder characterized by erythema, flushing, telangiectasia, papules and pustules, phymatous changes, and ocular involvement. The aim of this study was to examine all published research articles in which botulinum toxin was used to treat rosacea and to evaluate the efficacy and safety of this treatment. Methods PubMed, Embase, Cochrane Library, and Web of Science database were used to identify articles eligible for systematic review on March 26, 2021. Prospective or retrospective studies which directly used botulinum toxin to treat rosacea were included and reviewed. Results Nine studies were included in this systematic review. Two were randomized controlled trials, graded as Level 2 for the quality of evidence. The total number of participants was 130, and the number of participants in each study ranged from 1 to 25. The improvement was observed in all studies in signs and symptoms compared with baseline. Adverse events were transitory and self-limited. Conclusion Botulinum toxin could have overall satisfying efficacy and safety in the treatment of rosacea, though limited by small sample size, imperfect study design, and short follow-up visits.

show abstract

Acne and rosacea: What's new for treatment?

Cited by 17 publications

References 11 publications

Characterization and Analysis of the Skin Microbiota in Rosacea: Impact of Systemic Antibiotics

Characterization and Analysis of the Skin Microbiota in Rosacea: Impact of Systemic Antibiotics

Rosacea Treatment: Review and Update

Use of Botulinum Toxin in Treating Rosacea: A Systematic Review

Contact Info

Product

Resources

About